Digital Biomanufacturing Market to Reach USD 55.6 Billion by 2035 from USD 21.1 Billion in 2024, Expanding at 9.2% CAGR

The global digital biomanufacturing market was valued at US$ 21.1 Bn in 2024 and is projected to grow at a CAGR of 9.2% from 2025 to 2035, crossing US$ 55.6 Bn by the end of 2035. Rising demand for biologics, continued advancement of digital manufacturing technologies, and the increasing adoption of data-driven production systems are driving the expansion of the market.

Digital biomanufacturing integrates advanced digital technologies into biomanufacturing processes to improve efficiency, quality, flexibility, scalability, and decision-making. Technologies such as artificial intelligence (AI), machine learning, Internet of Things (IoT), manufacturing execution systems (MES), process analytical technology (PAT), data analytics software, and digital twins are transforming conventional biomanufacturing operations.

The growing production requirements for monoclonal antibodies, vaccines, and cell and gene therapies are creating a strong need for manufacturing platforms that can respond efficiently to changing demand. At the same time, the shift toward personalized medicine is encouraging manufacturers to develop flexible production models capable of accommodating increasingly complex and individualized therapies.

→Discover Market Opportunities - Request Your Sample Copy Now: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86631

Analysts’ Viewpoint on the Digital Biomanufacturing Market

Increasing demand for biologics is creating a need for advanced manufacturing approaches that can improve production efficiency, scalability, and flexibility. Digital technologies are helping manufacturers address these requirements by enabling real-time monitoring, predictive analytics, automation, and data-driven decision-making.

AI and machine learning can analyze large volumes of manufacturing data to identify patterns and trends that may not be readily apparent through conventional monitoring. IoT technologies enable real-time data collection from equipment and sensors, while robotics can automate repetitive processes and reduce human error.

Regulatory developments are also encouraging the integration of digital technologies into biomanufacturing. Digital systems can support compliance, quality assurance, process monitoring, and data security within highly regulated manufacturing environments.

Another important development is the convergence of MES and PAT. MES provides real-time oversight of manufacturing operations, while PAT enables continuous monitoring and analysis of manufacturing processes. Their integration can provide a more flexible manufacturing environment capable of responding quickly to changing production requirements and personalized medicine demand.

Digital Biomanufacturing Market Introduction

Digital biomanufacturing refers to the integration of advanced digital technologies into biomanufacturing processes to improve efficiency, quality, flexibility, and operational decision-making. The approach uses interconnected software, analytical systems, automation technologies, and data-driven tools to streamline the production of biologics.

The manufacturing execution system (MES) is a central component of the digital biomanufacturing ecosystem. MES provides a comprehensive platform for managing and monitoring manufacturing operations in real time. It can connect production, quality management, and supply chain activities while helping ensure that production processes are executed according to established plans.

Process analytical technology (PAT) is another important technology within digital biomanufacturing. PAT enables real-time monitoring and control of manufacturing processes by collecting and analyzing process data. This allows manufacturers to identify deviations and make adjustments when necessary, supporting consistent product quality throughout production.

Data analytics software is also becoming increasingly important as biomanufacturing processes generate large volumes of operational data. Advanced algorithms and machine learning technologies can analyze this information to identify opportunities for optimizing products, processes, materials, and resources.

Digital twins represent another emerging technology. A digital twin creates a virtual representation of a physical process or system, allowing manufacturers to simulate potential operating conditions and outcomes before implementing changes in the physical manufacturing environment. This can support risk management and improve decision-making by enabling manufacturers to evaluate potential scenarios.

Together, these technologies form an interconnected digital ecosystem that makes biomanufacturing more efficient, responsive, flexible, and data-driven.

Increasing Demand for Biologics Boosts Digital Biomanufacturing Market Growth

The increasing demand for biologics is one of the primary factors driving the digital biomanufacturing market. Biologics include vaccines, monoclonal antibodies, and cell and gene therapies, which are increasingly important in the treatment of chronic conditions, autoimmune diseases, and various cancers.

Growing prevalence of these diseases, combined with the industry's transition toward personalized medicine, is increasing the need for flexible manufacturing capabilities. Personalized medicine emphasizes treatments tailored to individual patients, requiring manufacturing systems capable of accommodating variations in production requirements.

Digital biomanufacturing can help address these requirements by improving manufacturing efficiency, scalability, and operational flexibility. Technologies such as MES and PAT provide manufacturers with real-time data and rapid decision-making capabilities, enabling production processes to respond more effectively to changing demand.

The growing complexity of biologics is also increasing the importance of precision in manufacturing. Advanced automation and analytics can help manufacturers maintain process consistency and quality while managing increasingly sophisticated production processes.

Companies adopting digital biomanufacturing technologies can potentially improve their ability to scale operations, optimize processes, and support innovation. As demand for biologics continues to increase, digital manufacturing capabilities are becoming increasingly important to the broader biopharmaceutical manufacturing ecosystem.

Advancements in Digital Manufacturing Technologies Drive Market Expansion

Continuous technological development is creating new opportunities across digital biomanufacturing. Artificial intelligence and machine learning are increasingly being used to optimize production processes by analyzing large volumes of manufacturing data.

Machine learning algorithms can identify patterns and trends within process data, providing insights that can support process optimization and operational decision-making. These capabilities can help manufacturers better understand complex production environments and identify potential opportunities for improvement.

IoT technology is also playing an important role by enabling real-time data collection from equipment and sensors throughout biomanufacturing processes. Connected equipment can continuously transmit operational information, reducing dependence on manual monitoring and enabling faster responses to changes in production conditions.

Advanced robotics is another important component of digital manufacturing. Robotic systems can automate activities such as materials handling and assembly, helping reduce human error and production lead times. Robots can also operate alongside human workers, allowing skilled personnel to concentrate on complex activities requiring critical thinking and problem-solving.

The convergence of AI, machine learning, IoT, robotics, analytics, and automation is therefore transforming conventional biomanufacturing into a more connected and intelligent production environment.

Manufacturing Execution System (MES) Leads the Digital Biomanufacturing Market

The manufacturing execution system (MES) segment dominates the global digital biomanufacturing market due to its ability to provide real-time monitoring and control of manufacturing operations.

MES can function as a centralized source of information connecting production, quality assurance, and supply chain management. This integrated approach can improve operational workflows and provide stakeholders with timely information for making production decisions.

Compliance and quality assurance are particularly important in the highly regulated biopharmaceutical industry. MES can support these requirements by providing greater visibility into production activities and helping organizations manage manufacturing processes in a structured and traceable manner.

MES also provides the flexibility required to scale manufacturing operations according to demand. As demand for biologics continues to rise and production requirements become more complex, the ability to increase or decrease manufacturing capacity efficiently is becoming increasingly valuable.

→Explore Strategies & Trends - Request Full Report Access – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=86631

North America Leads the Digital Biomanufacturing Market

North America dominated the global digital biomanufacturing market in 2024 and is expected to maintain its leading position during the forecast period. The region benefits from a strong ecosystem comprising established biopharmaceutical companies, research institutions, technology providers, and organizations collaborating to advance manufacturing technologies.

Government support and favorable regulatory frameworks are also contributing to innovation in biomanufacturing. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) are supporting the integration of digital technologies into manufacturing processes, helping create an environment conducive to the adoption of innovative manufacturing approaches.

High levels of research and development investment are another important factor supporting regional growth. Public and private investments are contributing to research in bioprocessing and digital manufacturing technologies, including artificial intelligence, machine learning, and the Internet of Things.

The combination of a mature biopharmaceutical industry, advanced research capabilities, technology development, and supportive regulatory conditions positions North America as a key market for digital biomanufacturing.

Europe represents another important regional market, supported by its established pharmaceutical and biotechnology industries and focus on advanced manufacturing technologies. Asia Pacific is also expected to offer significant growth opportunities as biopharmaceutical production capabilities and digital technology adoption expand across countries such as China, India, Japan, and Australia.

Digital Biomanufacturing Market Segmentation

The global digital biomanufacturing market is segmented based on technology, deployment type, biologic type, application, and end-user.

By technology, the market is divided into manufacturing execution system (MES), process analytical technology (PAT), data analytics software, and digital twins. MES currently represents the leading technology segment, supported by its ability to provide real-time visibility and coordination across manufacturing operations.

Based on deployment type, the market is classified into cloud-based and on-premises solutions. The choice of deployment depends on factors such as infrastructure requirements, data management, security considerations, and operational preferences.

By biologic type, the market comprises vaccines, antibodies, cell and gene therapies, and others. Increasing demand for complex biologics and personalized therapies is creating opportunities for digital manufacturing platforms capable of supporting flexible production.

Based on application, the market is segmented into biomanufacturing process automation, remote equipment monitoring, digital bioreactor scaling, and others.

By end-user, the market includes biopharmaceutical companies, contract manufacturing organizations, and others.

Strategic Collaborations Strengthen Competitive Landscape

Companies operating in the digital biomanufacturing industry are increasingly pursuing strategic collaborations and partnerships to accelerate innovation and develop integrated manufacturing solutions.

Leading companies in the market include Cytiva (Danaher Corporation), Eppendorf SE, Sartorius AG, Merck KGaA, Aspen Technology Inc., Körber AG, AmpleLogic, Siemens, Thermo Fisher Scientific Inc., ABB, Bruker, Hamilton Company, Dassault Systèmes, Kymanox Corporation, Invert, Inc., and Genedata AG.

These companies are profiled based on company overview, financial performance, business strategies, product portfolio, business segments, sales footprint, subsidiaries or distributors, and recent developments.

Strategic collaborations are particularly important as manufacturers seek to integrate software, automation, analytical technologies, equipment, and data management capabilities into unified digital biomanufacturing ecosystems.

Key Developments in Digital Biomanufacturing

In April 2025, Sartorius Stedim Biotech entered into a collaboration with Tulip Interfaces to accelerate digital transformation in biopharmaceutical manufacturing. Under the partnership, the companies are combining their capabilities to develop Biobrain Operate, a next-generation suite of digital manufacturing applications designed to interface directly with Sartorius Stedim Biotech process equipment.

In January 2025, Cytiva announced a partnership with Cellular Origins to transform cell therapy manufacturing processes. The collaboration combines Cytiva's automated Sefia platform with Cellular Origins' automated robotic Constellation platform to create a digitally interconnected system incorporating quality control systems, remote digital controls, and analytics.

The combined system is intended to support cell and gene therapy manufacturers in scaling production to industrial levels while maintaining continuity between discovery, clinical development, and manufacturing processes.

These developments demonstrate the growing importance of interoperability, automation, remote monitoring, analytics, and digital connectivity in next-generation biomanufacturing.

Regional Landscape

The global digital biomanufacturing market covers North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America includes the U.S. and Canada, while Europe covers countries such as Germany, the U.K., France, Italy, and Spain. Asia Pacific includes China, Australia & New Zealand, India, and Japan, while Latin America includes Brazil and Mexico. The Middle East & Africa region includes GCC countries and South Africa.

North America is expected to remain a key market due to its established biopharmaceutical ecosystem, high R&D investment, technology infrastructure, and regulatory support. Meanwhile, Europe and Asia Pacific are positioned to contribute to market expansion as biopharmaceutical manufacturing becomes increasingly digitalized.

Future Outlook for the Digital Biomanufacturing Market

The global digital biomanufacturing market is projected to increase from US$ 21.1 Bn in 2024 to more than US$ 55.6 Bn by 2035, advancing at a CAGR of 9.2% from 2025 to 2035.

Increasing demand for biologics, including vaccines, antibodies, and cell and gene therapies, is expected to remain a fundamental growth driver. As biologics become more complex and personalized medicine expands, manufacturers require flexible production environments capable of responding rapidly to changing therapeutic requirements.

Digital technologies are providing the infrastructure needed to achieve this flexibility. MES can provide real-time operational visibility, PAT can enable continuous process monitoring, analytics can convert manufacturing data into actionable insights, and digital twins can support simulation and scenario analysis.

AI, machine learning, IoT, and robotics are further transforming biomanufacturing by enabling predictive analytics, connected equipment, automated processes, and reduced dependence on manual intervention. The convergence of these technologies is creating increasingly intelligent and responsive manufacturing environments.

Strategic collaborations between technology providers, equipment manufacturers, and biopharmaceutical companies are also expected to accelerate innovation. As regulatory frameworks continue to accommodate digital technologies and manufacturers prioritize efficiency, quality, scalability, and flexibility, adoption of digital biomanufacturing solutions is expected to expand substantially through 2035.

Buy Full Report Now: https://www.transparencymarketresearch.com/checkout.php?rep_id=86631<ype=S

→Explore Latest Research Reports by Transparency Market Research:

Multiomics Market

Epidermal Growth Factors (EGFs) Market

Next Generation Sequencers (NGS) Market

Genomic Surveillance/Sequencing Market

Exosome Isolation Market

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Media Contact: 

Abhishek Budholiya

Transparency Market Research Inc.

State Tower, 90 State Street, Suite 700,

Albany NY - 12207, United States

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com 

Sales Inquiries: sales@transparencymarketresearch.com

Media Inquiries: media@transparencymarketresearch.com